222 related articles for article (PubMed ID: 25322923)
21. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting.
Tariot PN; Cummings JL; Katz IR; Mintzer J; Perdomo CA; Schwam EM; Whalen E
J Am Geriatr Soc; 2001 Dec; 49(12):1590-9. PubMed ID: 11843990
[TBL] [Abstract][Full Text] [Related]
22. Management of patients with Alzheimer's disease plus cerebrovascular disease: 12-month treatment with galantamine.
Bullock R; Erkinjuntti T; Lilienfeld S;
Dement Geriatr Cogn Disord; 2004; 17(1-2):29-34. PubMed ID: 14560062
[TBL] [Abstract][Full Text] [Related]
23. Donepezil for Alzheimer's disease in clinical practice--The DONALD Study. A multicenter 24-week clinical trial in Germany.
Froelich L; Gertz HJ; Heun R; Heuser I; Jendroska K; Kornhuber J; Kurz A; Mueller-Thomsen T; Ries F; Waechtler C; Metz M; Goebel C
Dement Geriatr Cogn Disord; 2004; 18(1):37-43. PubMed ID: 15084792
[TBL] [Abstract][Full Text] [Related]
24. Efficacy of a medical food on cognition in Alzheimer's disease: results from secondary analyses of a randomized, controlled trial.
Kamphuis PJ; Verhey FR; Olde Rikkert MG; Twisk JW; Swinkels SH; Scheltens P
J Nutr Health Aging; 2011 Aug; 15(8):720-4. PubMed ID: 21968871
[TBL] [Abstract][Full Text] [Related]
25. A clinical study of lupron depot in the treatment of women with Alzheimer's disease: preservation of cognitive function in patients taking an acetylcholinesterase inhibitor and treated with high dose lupron over 48 weeks.
Bowen RL; Perry G; Xiong C; Smith MA; Atwood CS
J Alzheimers Dis; 2015; 44(2):549-60. PubMed ID: 25310993
[TBL] [Abstract][Full Text] [Related]
26. Cessation versus continuation of galantamine treatment after 12 months of therapy in patients with Alzheimer's disease: a randomized, double blind, placebo controlled withdrawal trial.
Scarpini E; Bruno G; Zappalà G; Adami M; Richarz U; Gaudig M; Jacobs A; Schäuble B
J Alzheimers Dis; 2011; 26(2):211-20. PubMed ID: 21606568
[TBL] [Abstract][Full Text] [Related]
27. Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe.
Feldman HH; Doody RS; Kivipelto M; Sparks DL; Waters DD; Jones RW; Schwam E; Schindler R; Hey-Hadavi J; DeMicco DA; Breazna A;
Neurology; 2010 Mar; 74(12):956-64. PubMed ID: 20200346
[TBL] [Abstract][Full Text] [Related]
28. Effect of the apolipoprotein E epsilon4 allele on the efficacy and tolerability of galantamine in the treatment of Alzheimer's disease.
Suh GH; Jung HY; Lee CU; Oh BH; Lee SK; Lee N; Kim J; Kee BS; Ko D; Kim YH; Ju YS; Hong I; Choi S;
Dement Geriatr Cogn Disord; 2006; 21(1):33-9. PubMed ID: 16254428
[TBL] [Abstract][Full Text] [Related]
29. Exploring effects of Souvenaid on cerebral glucose metabolism in Alzheimer's disease.
Scheltens NME; Briels CT; Yaqub M; Barkhof F; Boellaard R; van der Flier WM; Schwarte LA; Teunissen CE; Attali A; Broersen LM; van Berckel BNM; Scheltens P
Alzheimers Dement (N Y); 2019; 5():492-500. PubMed ID: 31650005
[TBL] [Abstract][Full Text] [Related]
30. Long-Term Safety and Efficacy of Bapineuzumab in Patients with Mild-to-Moderate Alzheimer's Disease: A Phase 2, Open-Label Extension Study.
Salloway S; Marshall GA; Lu M; Brashear HR
Curr Alzheimer Res; 2018; 15(13):1231-1243. PubMed ID: 30129411
[TBL] [Abstract][Full Text] [Related]
31. Safety and tolerability of the γ-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease.
Coric V; van Dyck CH; Salloway S; Andreasen N; Brody M; Richter RW; Soininen H; Thein S; Shiovitz T; Pilcher G; Colby S; Rollin L; Dockens R; Pachai C; Portelius E; Andreasson U; Blennow K; Soares H; Albright C; Feldman HH; Berman RM
Arch Neurol; 2012 Nov; 69(11):1430-40. PubMed ID: 22892585
[TBL] [Abstract][Full Text] [Related]
32. Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial.
Freund-Levi Y; Eriksdotter-Jönhagen M; Cederholm T; Basun H; Faxén-Irving G; Garlind A; Vedin I; Vessby B; Wahlund LO; Palmblad J
Arch Neurol; 2006 Oct; 63(10):1402-8. PubMed ID: 17030655
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety evaluation of HSD-1 inhibitor ABT-384 in Alzheimer's disease.
Marek GJ; Katz DA; Meier A; Greco N; Zhang W; Liu W; Lenz RA
Alzheimers Dement; 2014 Oct; 10(5 Suppl):S364-73. PubMed ID: 24418055
[TBL] [Abstract][Full Text] [Related]
34. Targeting synaptic dysfunction in Alzheimer's disease by administering a specific nutrient combination.
van Wijk N; Broersen LM; de Wilde MC; Hageman RJ; Groenendijk M; Sijben JW; Kamphuis PJ
J Alzheimers Dis; 2014; 38(3):459-79. PubMed ID: 23985420
[TBL] [Abstract][Full Text] [Related]
35. Efficacy of Souvenaid® Combined with Acetylcholinesterase Inhibitors in the Treatment of Mild Alzheimer's Disease.
García-Alberca JM; Gris E; de la Guía P; Mendoza S; de la Rica ML
J Alzheimers Dis; 2023; 91(4):1459-1469. PubMed ID: 36641676
[TBL] [Abstract][Full Text] [Related]
36. [Health claims for medical foods].
Katan MB
Ned Tijdschr Geneeskd; 2013; 157(24):A6471. PubMed ID: 23759182
[TBL] [Abstract][Full Text] [Related]
37. A multicentre, randomized, double-blind, placebo-controlled study to evaluate the efficacy, tolerability and safety of two doses of metrifonate in patients with mild-to-moderate Alzheimer's disease: the MALT study.
Dubois B; McKeith I; Orgogozo JM; Collins O; Meulien D
Int J Geriatr Psychiatry; 1999 Nov; 14(11):973-82. PubMed ID: 10556869
[TBL] [Abstract][Full Text] [Related]
38. A randomized controlled trial of high-dose vitamin D2 followed by intranasal insulin in Alzheimer's disease.
Stein MS; Scherer SC; Ladd KS; Harrison LC
J Alzheimers Dis; 2011; 26(3):477-84. PubMed ID: 21694461
[TBL] [Abstract][Full Text] [Related]
39. Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial.
Lannfelt L; Blennow K; Zetterberg H; Batsman S; Ames D; Harrison J; Masters CL; Targum S; Bush AI; Murdoch R; Wilson J; Ritchie CW;
Lancet Neurol; 2008 Sep; 7(9):779-86. PubMed ID: 18672400
[TBL] [Abstract][Full Text] [Related]
40. A 2-year open-label study of galantamine therapy in Chinese Alzheimer's disease patients in Hong Kong.
Chu LW; Yik PY; Mok W; Chung CP
Int J Clin Pract; 2007 Mar; 61(3):403-10. PubMed ID: 17313606
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]